Using Alzheimer's disease blood tests to accelerate clinical trial enrollment,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Using Alzheimer's disease blood tests to accelerate clinical trial enrollment
Alzheimer's & Dementia ( IF 14.0 ) Pub Date : 2022-08-07 , DOI: 10.1002/alz.12754
Suzanne E Schindler _{1,

2} , Yan Li _{1,

2} , Melody Li ₁ , Alyssa Despotis ₃ , Ethan Park ₁ , Liberty Vittert ₃ , Barton H Hamilton ₃ , Kyle B Womack _{1,

2} , Benjamin Saef ₁ , David M Holtzman _{1,

2,

4} , John C Morris _{1,

2} , Randall J Bateman _{1,

2,

4} , Mahendra R Gupta ₃

Affiliation

Screening potential participants in Alzheimer's disease (AD) clinical trials with amyloid positron emission tomography (PET) is often time consuming and expensive.

中文翻译：